ALZpath is transforming Alzheimer’s disease diagnosis
We’re changing what’s possible in Alzheimer’s care – giving patients and clinicians the time and clarity they need to act earlier.
Diagnosis Made Simple
Because knowing earlier changes everything
We deliver early and accurate detection of Alzheimer’s disease pathology through a simple blood test, allowing patients to take control of their health.
Advanced ALZpath-powered tests provide answers without invasive procedures, expensive imaging, and long wait times – years before symptoms emerge.
We believe everyone should understand the risk of developing Alzheimer’s disease.
ALZpath’s science powers Alzheimer’s blood tests that give patients the chance to act.
Why Early Matters
- A simple blood draw – noninvasive and easy to access
- Reliable and sensitive, matching traditional PET scans and cerebrospinal fluid (CSF) tests
- Enabling detection of Alzheimer’s disease pathology up to 15 years before symptoms emerge
Early answers mean more time. More choices. More life.
Built for Scale.
Designed for Access.
The demand for early Alzheimer’s detection is real – and growing fast. ALZpath meets this head-on by licensing our proprietary pTau217 antibody to leading diagnostic and life science companies and laboratories worldwide.
Our antibody powers tests from industry leaders including:
- Beckman Coulter Diagnostics
- Roche
- Alamar Biosciences
- Bio-Techne
- Quanterix
We also collaborate with leading CAP/CLIA labs like Neurocode to ensure testing is accurate, consistent, and available wherever it is needed.
Making early action possible for all.
Improving Lives
Together, we’re shaping a future where early Alzheimer’s disease diagnosis is accessible everywhere – transforming care, improving lives, and changing the trajectory of this disease on a global scale.
A Global Impact
Access Matters
Alzheimer’s disease and related diseases are expected to affect more than 150 million people worldwide by 2050. Alzheimer’s disease accounts for an estimated 60% to 80% of those cases – making it the leading cause of cognitive impairment globally.
Highly Sensitive, Highly Accurate
Our antibody detects pTau217 (phosphorylated tau 217) – a key protein modification in brain cells that appears early in the course of Alzheimer’s disease – well before symptoms appear. It is the scientific foundation behind the most accurate and scalable blood-based diagnostic tools.
Founded in 2020
Founded by leaders in science and philanthropy, ALZpath is a team of innovators, scientists, and clinicians united by one mission: Enable earlier answers for everyone, everywhere.